New Delhi: The Sputnik V team on Wednesday confirmed that the temporary delay in delivery thanks to production scale-up are going to be fully resolved in August.
“Sputnik V team confirms that thanks to a serious scale-up in vaccine production capacity temporary second component delivery delays that occurred due to this production scale-up are going to be fully resolved in August,” a handout read.
Mentioning the doubling of the capacity of Sputnik V in September, the discharge stated, “Sputnik V has built production partnership with producers in 14 countries and can additionally double its capacity in September because of our partnership with top producers including Serum Institute of India, the world’s largest vaccine producer.”
Further, the discharge added that a study by the Gamaleya Center published in Vaccines international medical journal showed that Sputnik V is one among the foremost efficient vaccines against coronavirus variants including Delta.
“Demand for Sputnik V worldwide remains very high thanks to its exceptional efficacy and safety also because the absence of any serious side effects, which are linked to the utilization of another vaccines. In countries where Sputnik V is employed as a part of national vaccination campaigns, notably in Argentina and Mexico, a gentle decline in COVID-19 cases is observed,” it read.
Further, the discharge mentioned the role of Sputnik V in vaccine combinations (mix and match approach), and said, “Sputnik V, which pioneered the heterogeneous boosting (“vaccine cocktail”) approach by using two different adenoviral vectors (Ad5 and Ad26) for 2 different shots, was first to supply a joint mix and match trial to a different producer when it made a suggestion to AstraZeneca on November 23, 2020.”
Joint Sputnik V and AstraZeneca trials are ongoing within the United Arab Emirates, Azerbaijan, and Argentina since February 2021. the first positive results were announced on July 30. More positive results on immunogenicity are expected in the week .
“Sputnik V will accelerate work with other vaccine producers on the combination and match approach, which triggers a robust and longer-lasting immune reaction . the primary component of Sputnik V (Sputnik Light) which demonstrated over 80% efficacy on its own, above many two-shot vaccines, are going to be offered to other vaccine producers as a part of our mix and match strategy,” the discharge mentioned.
Team Sputnik V also refuted media reports and said that not one country has cancelled a contract for the delivery. “On the other , the demand for Sputnik V continues to significantly increase thanks to its exceptional safety and efficacy as demonstrated through,” they said.
